This website uses cookies. If you do not want these cookies you can disable them here. Read more about our cookie statement.
Non-invasive imaging of kidney fibrosis using Fibrobodies presented as a highlight during the innovation showcase of of the World Molecular Imaging Congress
LinXis and AmsterdamUMC jointly present results on our Fibrobody® in experimental Pulmonary Arterial Hypertension at the 2025 Congress of the ERS.
Linxis joins the PHAEDRA-IMPACT consortium as industrial partner in “TheFireInPH”, a TKI PPP project with a budget of over EUR800k.
Read all about the preclinical validation of our lead Fibrobody® in the European Journal of Nuclear Medicine and Molecular Imaging.
With a total budget close to EUR1 million, the FibroTarget project aims to develop Fibrobody-Drug Conjugates (FDCs) for the treatment of pulmonary fibrosis.
On March 17th to March 19th we will attend the BioEurope Spring partnering event in Milano, Italy.
LinXis will attend EANM in Hamburg from October 19-23, where we will also present the preclinical results-to-date on our lead Fibrobody® in a Top Rated Oral Presentation.
We are proud to welcome Guus van Dongen as our full-time CSO.
